Our Research

Bio Technology

Please use selectors to filter reports

September 22, 2017
Equity Research Coverage

Race Oncology Limited (ASX: RAC) – Big Strides in the Re-Development of Bisantrene – Target Available for use in Europe & South Korea in 2 years

Our base case valuation for RAC remains at $0.44 per share. Our valuation is based on a fully diluted basis. The company is expected to generate revenue over the shortterm through the sale of Bisantrene under the NPP throughout the four above mentioned countries.RAC intends to make Bisantrene available for use in Europe and South Korea. The company is also seeking to gain approval by the FDA for its drug via the 505(b)(2) route....
Register to Dowload
March 19, 2017
Company Profile Reporting

Creso Pharma Limited (ASX: CPH) – Positioning For The Expanding Cannabis Market

CPH will develop, register and commercialise, in association with licenced partners, animal health and human food supplements manufactured from cannabis. The company currently generates a modest income from sale of products. These products have a low concentration of the hallucinogenic compound THC, but high concentrations of the other medicinal compounds found in the cannabis plant....
Register to Dowload
January 6, 2017
Equity Research Coverage

Creso Pharma Limited (ASX: CPH) – First Company to Import Medicinal Cannabis Product into Australia

While the company has taken significant steps to put themselves in a position to be a significant player in the emerging hemp extract and medicinal cannabis market, the company is in the early stages of growth and is operating in a highly competitive market. With the company undergoing product development and currently generating low levels of revenue, an investment in the company remains speculative...
Register to Dowload
November 16, 2016
Equity Research Coverage

Noxopharm Limited (ASX: NOX) – Dosage Formulation of Idronoxil – Innovative Design to Eliminate/ Reduce Drug Resistance for Cancer Treatments

The company is seeking to use a compound with which the Managing Director has significant experience and that has been used in clinical trials without any safety concerns. Dr. Dr. Kelly believes he has discovered the delivery method and formulation of Idronoxil that will result in NOX66 delivering the desired results....
Register to Dowload
January 6, 2015
Equity Research Coverage

Suda Limited – (ASX: SUD) – Delivering Drugs through Oral Sprays – Transaction focus in 2014

Since our Initiation of Coverage in February 2014, the company has made a number of advancements in the development of the product portfolio, particularly with respect to ArtiMistTM....
Register to Dowload
February 18, 2014
Equity Research Coverage

Suda Limited – (ASX: SUD) – Delivering Drugs through Oral Sprays – Transaction focus in 2014

SUD is a drug delivery company focusing on reformulating existing drugs into an oral spray for delivery through the oral mucosa. The company currently has a number of drugs under development including an oral spray for the treatment of malaria in children and oral sprays for migraine, erectile dysfunction, chemotherapy-induced nausea, pulminary arterial hypertension and pre-procedural anxiety...
Register to Dowload